{
  "id": 11270456,
  "title": "Assessing Pathology and How It Impacts Early HER2 Breast Cancer Treatment",
  "url": "https://urgent.news/2026/10/01/assessing-pathology-and-how-it-impacts-early-her2-breast-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T19:57:32.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/beyond-diagnosis/her2-ebc/123235"
  },
  "original_language": "en",
  "account": "In the first episode of Beyond Diagnosis, Cleveland Clinic breast oncologist Dr. Megan Kruse discusses interpreting pathology results for early HER2-positive breast cancer patients. The immunohistochemistry results, graded from 0 to 3, determine if a patient is HER2-negative (0 or 1+) or HER2-positive (3+). For the equivocal 2+ results, FISH (fluorescence in situ hybridization) testing is often used to clarify the situation.\n\nWhen a patient's results are equivocal, Dr. Kruse typically conducts additional testing, such as repeating the biopsy or consulting other pathologists. These cases are often presented at a tumor board, where multiple specialists review the situation to determine the best course of action.\n\nThe degree of HER2 gene amplification or protein overexpression is crucial, as it directly impacts the sensitivity of HER2-targeted therapies. The more protein present, the more effective these medications are likely to be.\n\nInitially, HER2 status was considered binary, with patients either positive or negative. However, the concept of HER2-low and HER2-ultralow has emerged, referring to a range of HER2-positive cancers with lower protein levels. While these classifications have become more common, they primarily affect treatment decisions in metastatic breast cancer and do not change the staging, prognosis, or treatment patterns for early-stage breast cancer. For early-stage HER2-positive and hormone receptor-positive patients, the focus remains on the standard positive and negative classifications.",
  "summary": "(MedPage Today) -- In \"Beyond Diagnosis: Early HER2-Positive Breast Cancer,\" Cleveland Clinic breast oncologist Megan Kruse, MD, and host John Mangels discuss how clinicians can navigate increasingly complex treatment decisions while helping patients...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "MyJoyOnline Ghana",
        "title": "Breast cancer diagnosis is not a life sentence – Gender Minister urges early treatment",
        "url": "https://urgent.news/2026/10/01/breast-cancer-diagnosis-is-not-a-life-sentence-gender-minister-urges",
        "published": "2026-10-01T19:17:14.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}